Aaron Hakim1,2,3, Matthew Moll3,4, Joseph Brancale5, Jiangyuan Liu3, Jessica A Lasky-Su3, Edwin K Silverman3,4, Silvia Vilarinho5, Z Gordon Jiang1,2, Yered H Pita-Juárez6, Ioannis S Vlachos6, Xuehong Zhang3, Fredrik Åberg7, Nezam H Afdhal2, Brian D Hobbs3,4, Michael H Cho1,3,4. 1. Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA. 2. Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Boston, MA. 3. Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA. 4. Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA. 5. Departments of Internal Medicine, Section of Digestive Diseases, and of Pathology, Yale School of Medicine, New Haven, CT. 6. Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA. 7. Transplantation and Liver Surgery Clinic, Helsinki University Hospital, Helsinki, Finland.
Abstract
BACKGROUND AND AIMS: Most of the genetic basis of chronic liver disease remains undiscovered. APPROACH AND RESULTS: To identify genetic loci that modulate the risk of liver injury, we performed genome-wide association studies on circulating levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin across 312,671 White British participants in the UK Biobank. We focused on variants associated with elevations in all four liver biochemistries at genome-wide significance (P < 5 × 10-8 ) and that replicated using Mass General Brigham Biobank in 19,323 European ancestry individuals. We identified a genetic locus in mitochondrial glycerol-3-phosphate acyltransferase (GPAM rs10787429) associated with increased levels of ALT (P = 1.4 × 10-30 ), AST (P = 3.6 × 10-10 ), ALP (P = 9.5 × 10-30 ), and total bilirubin (P = 2.9 × 10-12 ). This common genetic variant was also associated with an allele dose-dependent risk of alcohol-associated liver disease (odd ratio [OR] = 1.34, P = 2.6 × 10-5 ) and fatty liver disease (OR = 1.18, P = 5.8 × 10-4 ) by International Classification of Diseases, 10th Revision codes. We identified significant interactions between GPAM rs10787429 and elevated body mass index in association with ALT and AST (P = 7.1 × 10-9 and 3.95 × 10-8 , respectively), as well as between GPAM rs10787429 and weekly alcohol consumption in association with ALT, AST, and alcohol-associated liver disease (P = 4.0 × 10-2 , 1.6 × 10-2 , and 1.3 × 10-2 , respectively). Unlike previously described genetic variants that are associated with an increased risk of liver injury but confer a protective effect on circulating lipids, GPAM rs10787429 was associated with an increase in total cholesterol (P = 2.0 × 10-17 ), LDL cholesterol (P = 2.0 × 10-10 ), and HDL cholesterol (P = 6.6 × 10-37 ). Single-cell RNA-sequencing data demonstrated hepatocyte-predominant expression of GPAM in cells that co-express genes related to VLDL production (P = 9.4 × 10-103 ). CONCLUSIONS: Genetic variation in GPAM is associated with susceptibility to liver injury. GPAM may represent a therapeutic target in chronic liver disease.
BACKGROUND AND AIMS: Most of the genetic basis of chronic liver disease remains undiscovered. APPROACH AND RESULTS: To identify genetic loci that modulate the risk of liver injury, we performed genome-wide association studies on circulating levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin across 312,671 White British participants in the UK Biobank. We focused on variants associated with elevations in all four liver biochemistries at genome-wide significance (P < 5 × 10-8 ) and that replicated using Mass General Brigham Biobank in 19,323 European ancestry individuals. We identified a genetic locus in mitochondrial glycerol-3-phosphate acyltransferase (GPAM rs10787429) associated with increased levels of ALT (P = 1.4 × 10-30 ), AST (P = 3.6 × 10-10 ), ALP (P = 9.5 × 10-30 ), and total bilirubin (P = 2.9 × 10-12 ). This common genetic variant was also associated with an allele dose-dependent risk of alcohol-associated liver disease (odd ratio [OR] = 1.34, P = 2.6 × 10-5 ) and fatty liver disease (OR = 1.18, P = 5.8 × 10-4 ) by International Classification of Diseases, 10th Revision codes. We identified significant interactions between GPAM rs10787429 and elevated body mass index in association with ALT and AST (P = 7.1 × 10-9 and 3.95 × 10-8 , respectively), as well as between GPAM rs10787429 and weekly alcohol consumption in association with ALT, AST, and alcohol-associated liver disease (P = 4.0 × 10-2 , 1.6 × 10-2 , and 1.3 × 10-2 , respectively). Unlike previously described genetic variants that are associated with an increased risk of liver injury but confer a protective effect on circulating lipids, GPAM rs10787429 was associated with an increase in total cholesterol (P = 2.0 × 10-17 ), LDL cholesterol (P = 2.0 × 10-10 ), and HDL cholesterol (P = 6.6 × 10-37 ). Single-cell RNA-sequencing data demonstrated hepatocyte-predominant expression of GPAM in cells that co-express genes related to VLDL production (P = 9.4 × 10-103 ). CONCLUSIONS: Genetic variation in GPAM is associated with susceptibility to liver injury. GPAM may represent a therapeutic target in chronic liver disease.
Authors: Noura S Abul-Husn; Xiping Cheng; Alexander H Li; Yurong Xin; Claudia Schurmann; Panayiotis Stevis; Yashu Liu; Julia Kozlitina; Stefan Stender; G Craig Wood; Ann N Stepanchick; Matthew D Still; Shane McCarthy; Colm O'Dushlaine; Jonathan S Packer; Suganthi Balasubramanian; Nehal Gosalia; David Esopi; Sun Y Kim; Semanti Mukherjee; Alexander E Lopez; Erin D Fuller; John Penn; Xin Chu; Jonathan Z Luo; Uyenlinh L Mirshahi; David J Carey; Christopher D Still; Michael D Feldman; Aeron Small; Scott M Damrauer; Daniel J Rader; Brian Zambrowicz; William Olson; Andrew J Murphy; Ingrid B Borecki; Alan R Shuldiner; Jeffrey G Reid; John D Overton; George D Yancopoulos; Helen H Hobbs; Jonathan C Cohen; Omri Gottesman; Tanya M Teslovich; Aris Baras; Tooraj Mirshahi; Jesper Gromada; Frederick E Dewey Journal: N Engl J Med Date: 2018-03-22 Impact factor: 91.245
Authors: Susanne Neschen; Katsutaro Morino; Linda E Hammond; Dongyan Zhang; Zhen-Xiang Liu; Anthony J Romanelli; Gary W Cline; Rebecca L Pongratz; Xian-Man Zhang; Cheol S Choi; Rosalind A Coleman; Gerald I Shulman Journal: Cell Metab Date: 2005-07 Impact factor: 27.287
Authors: J Gelernter; H R Kranzler; R Sherva; L Almasy; R Koesterer; A H Smith; R Anton; U W Preuss; M Ridinger; D Rujescu; N Wodarz; P Zill; H Zhao; L A Farrer Journal: Mol Psychiatry Date: 2013-10-29 Impact factor: 15.992
Authors: John C Chambers; Weihua Zhang; Joban Sehmi; Xinzhong Li; Mark N Wass; Pim Van der Harst; Hilma Holm; Serena Sanna; Maryam Kavousi; Sebastian E Baumeister; Lachlan J Coin; Guohong Deng; Christian Gieger; Nancy L Heard-Costa; Jouke-Jan Hottenga; Brigitte Kühnel; Vinod Kumar; Vasiliki Lagou; Liming Liang; Jian'an Luan; Pedro Marques Vidal; Irene Mateo Leach; Paul F O'Reilly; John F Peden; Nilufer Rahmioglu; Pasi Soininen; Elizabeth K Speliotes; Xin Yuan; Gudmar Thorleifsson; Behrooz Z Alizadeh; Larry D Atwood; Ingrid B Borecki; Morris J Brown; Pimphen Charoen; Francesco Cucca; Debashish Das; Eco J C de Geus; Anna L Dixon; Angela Döring; Georg Ehret; Gudmundur I Eyjolfsson; Martin Farrall; Nita G Forouhi; Nele Friedrich; Wolfram Goessling; Daniel F Gudbjartsson; Tamara B Harris; Anna-Liisa Hartikainen; Simon Heath; Gideon M Hirschfield; Albert Hofman; Georg Homuth; Elina Hyppönen; Harry L A Janssen; Toby Johnson; Antti J Kangas; Ido P Kema; Jens P Kühn; Sandra Lai; Mark Lathrop; Markus M Lerch; Yun Li; T Jake Liang; Jing-Ping Lin; Ruth J F Loos; Nicholas G Martin; Miriam F Moffatt; Grant W Montgomery; Patricia B Munroe; Kiran Musunuru; Yusuke Nakamura; Christopher J O'Donnell; Isleifur Olafsson; Brenda W Penninx; Anneli Pouta; Bram P Prins; Inga Prokopenko; Ralf Puls; Aimo Ruokonen; Markku J Savolainen; David Schlessinger; Jeoffrey N L Schouten; Udo Seedorf; Srijita Sen-Chowdhry; Katherine A Siminovitch; Johannes H Smit; Timothy D Spector; Wenting Tan; Tanya M Teslovich; Taru Tukiainen; Andre G Uitterlinden; Melanie M Van der Klauw; Ramachandran S Vasan; Chris Wallace; Henri Wallaschofski; H-Erich Wichmann; Gonneke Willemsen; Peter Würtz; Chun Xu; Laura M Yerges-Armstrong; Goncalo R Abecasis; Kourosh R Ahmadi; Dorret I Boomsma; Mark Caulfield; William O Cookson; Cornelia M van Duijn; Philippe Froguel; Koichi Matsuda; Mark I McCarthy; Christa Meisinger; Vincent Mooser; Kirsi H Pietiläinen; Gunter Schumann; Harold Snieder; Michael J E Sternberg; Ronald P Stolk; Howard C Thomas; Unnur Thorsteinsdottir; Manuela Uda; Gérard Waeber; Nicholas J Wareham; Dawn M Waterworth; Hugh Watkins; John B Whitfield; Jacqueline C M Witteman; Bruce H R Wolffenbuttel; Caroline S Fox; Mika Ala-Korpela; Kari Stefansson; Peter Vollenweider; Henry Völzke; Eric E Schadt; James Scott; Marjo-Riitta Järvelin; Paul Elliott; Jaspal S Kooner Journal: Nat Genet Date: 2011-10-16 Impact factor: 38.330
Authors: Debbie Hicks; Anna Sarkozy; Nuria Muelas; Katrin Köehler; Angela Huebner; Gavin Hudson; Patrick F Chinnery; Rita Barresi; Michelle Eagle; Tuomo Polvikoski; Geraldine Bailey; James Miller; Aleksander Radunovic; Paul J Hughes; Richard Roberts; Sabine Krause; Maggie C Walter; Steven H Laval; Volker Straub; Hanns Lochmüller; Kate Bushby Journal: Brain Date: 2011-01 Impact factor: 13.501
Authors: Sara Crespo Yanguas; Tereza C da Silva; Isabel V A Pereira; Michaël Maes; Joost Willebrords; Valery I Shestopalov; Bruna M Goes; Marina Sayuri Nogueira; Inar Alves de Castro; Guilherme R Romualdo; Luís F Barbisan; Eva Gijbels; Mathieu Vinken; Bruno Cogliati Journal: Arch Toxicol Date: 2018-07-09 Impact factor: 5.153